Dr. Philip on Olaratumab for Soft Tissue Sarcoma

Tony Philip, MD
Published: Friday, Nov 06, 2015



Tony Philip, MD, medical oncologist, Monter Cancer Center of the North Shore-LIJ Cancer Institute, assistant professor of Medicine, Hofstra-North Shore LIJ School of Medicine and NYIT College of Osteopathic Medicine, discusses approved and emerging agents for soft tissue sarcomas.

Trabectedin (Yondelis) received FDA approval for liposacoma and leiomyosarcoma, while the breast cancer agent eribulin (Halaven) is being studied in soft tissue sarcoma.

An agent being investigated in an ongoing phase III trial is olaratumab in combination with doxorubicin in advanced soft tissue sarcoma, which has demonstrated promising early-phase data. Olaratumab is a novel agent that could potentially be one of the first new drugs to add benefit to doxorubicin, which has been a standard treatment for several years.

<<< View more from the 2015 CFS Annual Meeting



Tony Philip, MD, medical oncologist, Monter Cancer Center of the North Shore-LIJ Cancer Institute, assistant professor of Medicine, Hofstra-North Shore LIJ School of Medicine and NYIT College of Osteopathic Medicine, discusses approved and emerging agents for soft tissue sarcomas.

Trabectedin (Yondelis) received FDA approval for liposacoma and leiomyosarcoma, while the breast cancer agent eribulin (Halaven) is being studied in soft tissue sarcoma.

An agent being investigated in an ongoing phase III trial is olaratumab in combination with doxorubicin in advanced soft tissue sarcoma, which has demonstrated promising early-phase data. Olaratumab is a novel agent that could potentially be one of the first new drugs to add benefit to doxorubicin, which has been a standard treatment for several years.

<<< View more from the 2015 CFS Annual Meeting


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x